Objectives: The aim of the study was to develop the three-dimensional (3D) evidence network plot systemda novel web-based interactive 3D tool to facilitate the visualization and exploration of covariate distributions and imbalances across evidence networks for network meta-analysis (NMA).
Introduction
Network meta-analysis (NMA) is an increasingly popular statistical method used for estimating the comparative efficacy of all treatments of interest for a given condition, by simultaneously synthesizing data from all relevant randomized controlled trials (RCTs) [1] . Such analyses are commonly used to identify the most effective treatments and inform economic decision models to estimate the relative cost-effectiveness of the treatment options.
Like all statistical modeling, NMA makes a number of assumptions that, if not satisfied by the data being synthesized, can lead to erroneous results and misleading conclusions [2] . The first assumption that needs satisfying is that the network is connected which can be checked by constructing a network diagram [3] . More generally, evidence network diagrams are commonly used for visualizing the available evidence base for the purpose of assessing the feasibility of the metaanalysis and understanding the strength and diversity of the evidence available. A conventional network diagram consists of ''nodes'' representing the treatments of interest and edges representing available direct comparisons between pairs of interventions and is a key component of global NMA reporting checklists [4] . All nodes should be connected to form a single network via edges and any nodes which are not connected should be excluded. The amount of available evidence can also be presented in network diagrams by ''weighting'' the nodes and edges using different node sizes and line thicknesses [5] .
This article describes a three-dimensional (3D) evidence network plot systemda novel, freely accessible, web-based package to facilitate the exploration of covariate distributions and imbalances across evidence networks in NMA.
What this adds to what was known?
The primary innovation which allows for the extensions to evidence networks and improvements is the use of a 3D graphical environment, incorporating the graphical representation of covariates on a third ''z''-axis.
We believe this work to be the first application of a 3D graphical environment to evidence networks in NMA.
What is the implication and what should change now?
We propose that the 3D evidence network plot system will facilitate the exploration of covariate distributions and imbalances across evidence networks and be of most value in the context of supporting NMA feasibility/validity assessments and to aid in the interpretation of NMA results to a wide audience.
Further assumptions of NMA relate to the comparability of the studies being combined. As for pairwise metaanalysis, differences in the results of studies (beyond that expected by chance) within each (pairwise) treatment comparison are described as between-study heterogeneity. Such variability in study results can lead to inconsistency in treatment estimates across different comparisons in an NMA, where estimates of comparative effectiveness differ between those from direct comparisons and those derived from indirect comparison routes through the network [6] . Although heterogeneity and inconsistency random-effect (RE) terms can be included in NMA models to allow for them [7] , results can become increasingly difficult to interpret as the number and magnitude of such terms increase. This can lead to challenging issues, in terms of limiting the ability to generalize from the results [8] , for both decision makers [9] and for designers of further studies that are intended to update the evidence base in the future [10, 11] . Therefore, it is highly desirable to explain the causes and magnitude of heterogeneity and inconsistency rather than simply accommodate them.
Heterogeneity and inconsistency can frequently be explained by the differences in trial design and the conduct of the individual trials included in the NMA. Assuming summary information from published trial results is being used for the NMA rather than individual patient data [12] , it may be possible to identify causes of heterogeneity and inconsistency by extracting information on study-and aggregate patient-level characteristics (e.g., duration of treatment or duration of condition before randomization). Such variables are often described as potential effect modifiers, and if these impact the effectiveness of the interventions of interest, treatment by covariate interactions can be included in the NMA model [7] . Treatment-covariate interactions can be used to explain and reduce heterogeneity and inconsistency in the same way as they are used in metaregression for pairwise meta-analysis [13] . In addition, when treatment by covariate interactions relating to patient characteristics are identified, it implies that treatment efficacy varies between patients. Therefore, optimal treatment decisions could vary across patient groups depending on their characteristics. In the current paper, we focus on potential effect modifiers which are expressed on a continuous scale (including dichotomous patient-level covariates aggregated at the study level, e.g., % of males), although we note that categorical variables (e.g., individual indicators of study quality) can also be considered using a regression framework and plots including these have been considered elsewhere [14] . Regression modeling is generally superior to subgroup analyses as it allows a holistic analysis, exploring the impact of covariates on all of the data, and allows the simultaneous consideration of multiple (continuous and categorical) covariates [8] . However, it should not be forgotten that regressing study-level summary covariate information on study-level average treatment effects is potentially susceptible to ecological bias.
A recent publication [14] , outlining a process for assessing the feasibility of conducting a valid NMA, highlighted the importance of assessing whether there are differences in treatment, patient, and outcome characteristics across comparisons that may affect the summary measures of treatment effects relative to an overall reference treatment. These potential effect modifiers may be known or suspected a priori or identified post hoc. Visually assimilating, exploring, and interpreting the distribution of covariate values across trials in an NMA is challenging due to the complexities of representing the network structure simultaneously alongside study-level covariate values. Although multiple plots could more easily be constructed for individual comparisons within the network, these are of limited use because many will be sparse and uninformative, and each plot only provides a subset of the required information. A holistic approach is required to assess the distribution of covariate values across the whole evidence network.
Cope et al. [14] present what we believe to be the first published attempt to present such information graphically for categorical and aggregate patient-level dichotomous covariates (i.e., expressed as a %). This was achieved by including pie-charts for each study close to the relevant comparison edge on a network diagram (see Cope et al. Figs. 4 and 5) . Although we acknowledge the utility of such an approach, we find assimilating the information from such displays challenging, particularly as it is not always clear which comparisons certain study pie-charts relate to. Furthermore, no method of displaying information from continuous covariates is proposed.
In this paper, we present a novel, interactive, freely accessible, web-based package to present continuous and aggregate patient-level dichotomous covariate information superimposed on an evidence network. We see our work as complementary to that previously discussed [14] , but we believe our method is easier to interpret for aggregate patient-level dichotomous covariate information (the context in which both approaches could be used) as it circumvents the issues highlighted above. The primary innovation underlying the suggested improvements is the use of an interactive three-dimensional (3D) graphical environment. Such 3D models are easier to interpret when they can be rotated rather than the reliance on static images. The readers of this publication are encouraged to explore the tool in conjunction with this paper (available at http:// 3dnma.com/plot).
In the current paper, Section 2 outlines the rationale for and features of the software tool we have developed; Section 3 introduces the first illustrative NMA example from rheumatoid arthritis (RA), which has a relatively simple star-shaped evidence network and is presented as an introduction to the concept of the 3D network plot system using disease duration and baseline risk as two continuous covariates of interest [8] ; Section 4 introduces a second example in advanced breast cancer, taken from the paper by Cope et al. [14] . Here, we graphically present one of the continuous covariates considered by Cope et al. (not originally presented graphically) and an aggregate dichotomous patient-level covariatevisceral metastases. The latter was presented visually by Cope et al., and we report a comparison with our 3D network plot system. Section 5 introduces advanced applications of the system whereby we demonstrate the reduction of network data to a single summary covariate per treatment contrast and incorporate data relating to the precision of the outcome data.
Features of the 3D network plot system
The 3D network plot system allows the incorporation of a third ''z''-axis to display covariate bars for each trial included within a network. The covariate bars for each study are placed on the edges of the relevant comparisons and projected on the third dimension.
First, a data set is uploaded to the system in the form of a Microsoft Excel sheet; a template can be downloaded from the system. When a covariate is not selected, the system produces a conventional two-dimensional (2D) network diagram. This allows for examination of the network structure, instantaneous removal of treatment nodes from the data set, and for conducting sensitivity analyses or producing focused views on a proportion of a complex network. When a covariate is selected, the system incorporates a third z-axis and ''bars'' to represent the covariate measure for each trial. This produces a 3D representation which allows for the distribution of covariate effects for each comparison to be simultaneously displayed. The system can hold multiple covariates, and each covariate can be selected from a drop-down menu. The system also features zoom functionality and an automatic rotation function (which can be used simultaneously with other manual controls) to facilitate the exploration of data.
Following the initial input of data, many aspects can be manually configured. This includes the position of the treatment nodes on the xey axis and the coloring of the nodes; the principal view can be centered on any treatment node of interest. The treatment nodes and treatment contrasts can be weighted to reflect the volume of available evidence. The covariate name, value, scaling, and units can be amended, in addition to the width of the covariate bars. The distance and positioning of the covariate bars across the treatment contrasts can also be modified, and the color can be changed to represent positive and negative values (relative to a reference value). Finally, the background grid feature and covariate labeling elements can be toggled on and off. All manual changes within the system can be saved and reloaded (as ''raw data''), and the system is able to generate figures in Portable Network Graphics format.
The software can be accessed at http://3dnma.com/plot and requires a user to register with their email address. The data sets for the examples used within this publication can be selected and loaded from within the system via a drop-down menu (example data sets 1e6). A full instruction manual is also available and can be downloaded from within the system.
Example 1: rheumatoid arthritis
The first example data set includes trials from a review of the NICE technology appraisal for certolizumab pegol (CZP) for the treatment of RA in patients who had failed diseasemodifying antirheumatic drugs (DMARDs) [15] . The data set includes 12 methotrexate (MTX) controlled trials comparing seven different treatments (placebo þ MTX, adalimumab þ MTX, CZP þ MTX, etanercept þ MTX, infliximab þ MTX, rituximab þ MTX, and tocilizumab þ MTX), forming a ''star''-shaped network where all comparisons are relative to placebo.
The data set was used as an example in the NICE guidance on methods for meta-regression for the outcome of American College of Rheumatology 50% (ACR50) at 6 months [8] . Two potential sources of effect modification are explored in the NICE guidanceedisease duration and the baseline risk of ACR50. Baseline risk is defined as the risk of ACR50 in the placebo arm of each trial.
Disease duration
Screenshots from the covariate visualizer of the evidence network and an evidence network incorporating information on the average disease duration from each study are shown in Figures 1 and 2 . A 2D view from the covariate visualizer (the xey plane with no third z-axis displayed) is shown in Fig. 1 and essentially represents a standard 2D network plot; the grid function is not displayed in this example. Fig. 2 shows the inclusion of the third (z) axis and the addition of covariate ''bars''dthe grid is also added on this example to aid the interpretation of the image in 3D. A single bar on the z-axis represents the covariate level of a single trial on the relevant edges connecting the treatment nodes compared in that trial. For example, the RAPID 1 and RAPID 2 trials compared placebo þ MTX with CZP þ MTX. Therefore, the two bars representing each of these trials lie on the edge connecting the placebo þ MTX node with CZP þ MTX. The disease duration for each trial has been centered on the mean disease duration across all trials of the network (8.21 years or 98.5 months). Consequently, in this example, the values on the z-axis may be positive or negative. Negative covariate values (representing trials in which disease duration is lower than the mean across all trials of the network) are presented as red bars, and positive values (representing trials in which disease duration is higher than the mean across the network) are presented as green bars. This further aids the interpretation of the distribution of the covariates across the network.
Disease duration was identified as a potential source of effect modification [8] . Previous studies in RA have demonstrated that shorter disease duration is associated with smaller treatment effects compared with a longer disease duration [16] .
In Fig. 2 , it is evident that there is considerable variability in the mean disease duration of patients enrolled in the RCTs included in the network. The studies with the most extreme values are immediately identifiable as Weinblatt 1999 (high value) and the CHARISMA trial (low value). Importantly, it can be clearly seen that this variability is systematic. For example, the RAPID 1 and 2 trials, which compared CZP þ MTX with placebo þ MTX, were both conducted in patients with shorter disease duration compared with the mean disease duration of the network. Thus, in this network, there is likely to be an unfavorable bias against CZP þ MTX as a shorter disease duration is associated with smaller treatment effects [16] . A similar scenario can also be observed for tocilizumab þ MTX. The single trial (Weinblatt 1999) which compares etanercept þ MTX with placebo þ MTX was conducted in patients with the longest disease duration of all the trials in the network. Thus, there is likely to be a favorable bias for etanercept þ MTX in this network compared with other DMARDs as longer disease duration is associated with greater treatment effects [8, 16] .
Although the meta-regression models presented by Dias et al. were not strongly supported by the trial data, the estimate of the interaction coefficient from the RE model did not include the null value within its 95% credible interval (CrI) [0.14 (95% CrI: 0.01, 0.26)] [8] . Thus, consistent with the findings from larger studies in RA, the interaction coefficient from the RE adjusted model suggests that for each 1-year unit increase in disease duration, the log odds ratio (OR) of each comparator vs. placebo þ MTX increases by 0.14 (i.e., larger treatment effects are associated with longer disease duration). Therefore, in this example, the implications of disease duration interaction with treatment effects should be considered for the decision model.
Baseline risk
As the meta-regression models adjusting for disease duration were not strongly supported by the RA data set from the technology appraisal, Dias et al. [8] recommended that further explanations of the causes of heterogeneity should be sought. Baseline risk is the underlying risk of the outcome of interest within a study population and represents a summary of both known and unknown risk factors. Baseline risk is a potentially important source of heterogeneity, particularly among studies where the baseline risk varies.
The screenshots from the data set visualized in the covariate visualizer are shown in Figures 3 and 4. Fig. 3 demonstrates the view along the xez plane, and Fig. 4 incorporates all three axes. Together, these figures highlight considerable variability in baseline risk across the trials of the network. Note, this particular visualization is only possible when all trials contain a common comparator treatment arm, such as that seen in ''star''-shaped networks. In this example, two trials (Abe 2006 and CHARISMA) exhibit higher baseline risks compared with the other trials of the network. This could be a potential cause for concern highlighting unfavorable bias toward the active treatments of these trials. The baseline risk models explored by Dias et al. using the RA data set suggested strong interaction effects between the baseline risk of ACR50 and relative treatment effects; this relationship should be incorporated in costeffectiveness analyses [8] . The estimate of the interaction coefficient from the RE model suggested that for each one unit (the difference from 100% to 0%) increase in the baseline log odds of ACR50, the log OR of each comparator vs. placebo þ MTX decreased by 0.95 (i.e., the greater the ACR50 response in the placebo þ MTX arm the smaller the treatment effect).
Example 2: advanced breast cancer
The second data set is the case study presented by Cope et al. which allows for the comparison of everolimus in combination with hormonal therapy with alternative therapies in terms of progression-free survival (PFS) in women with advanced breast cancer [14] . The data set consists of 24 RCTs which form a connected evidence network for the PFS outcome (which include hormonal and chemotherapy comparators). Data for several potential effect modifiers for each trial within the network are tabulated in Cope et al. [14] . This approach is consistent with the common format of reporting potential treatment effect modifiers in NMA publications which can be difficult to interpret. In addition, Cope et al. visually presented two of the aggregate dichotomous patient-level covariates (hormone receptor status and visceral metastases) as a pie-chart for each study, close to the relevant comparison edge on a network diagram (see Cope et al. Figs. 4 and 5) .
Cope et al. reported that differences within and across the treatment comparisons were observed in terms of estrogen receptor positive status, exposure to prior hormonal therapies, exposure to prior chemotherapies, and visceral metastases [14] . However, Cope et al. also reported that differences in performance status and age were less prominent, although differences in postmenopausal status, human epidermal growth factor 2 status, and types of hormonal therapies were noted [14] . In the following sections, we present one of the continuous covariates considered by Cope et al. [14] and an aggregate dichotomous patient-level covariate-visceral metastases. The latter was presented visually by Cope et al. [14] , and we contrast our approach with theirs.
Continuous covariate-median age
We have explored all the potential treatment effect modifiers presented in Cope et al. [14] as 3D network plots. Indeed, as suggested by Cope et al. [14] , the differences in terms of age across the trials appear to be less prominent than those observed with the other potential treatment effect modifiers. On display of the median age covariate within the 3D network plot system, it is immediately evident that there is relatively little variability in median age across the trials of the evidence network; in this example, the median age values across the trials have not been centered to a reference value in the 3D network plot system, and therefore, all bars are represented in green as the default color for positive values (Fig. 5) . However, it is easy to identify the treatment comparisons associated with the most extreme median age values (Fig. 5) . For example, the median age of patients in the O'Shaughnessy 2001 trial (bar has been colored red to highlight the trial in Fig. 5 ) is 70 years. This is the highest across the network and is 10 years greater than the mean of median ages (60 years) across the trials of the network. The O'Shaughnessy 2001 trial is the only study that contributes to the direct comparison of cyclophosphamide þ MTX þ fluorouracil vs. capecitabine (CAP). This could lead to a potential bias in comparisons of CAP with other treatments of interest depending on the potential direction of effect modification by age. The median age of patients in the Ingle 1982 trial (bar has been colored yellow to highlight the trial in Fig. 5 ) is 49 years, which is the lowest across the network and is 11 years below the mean of median ages. However, Ingle 1982 is one of three trials contributing evidence for the direct comparison of tamoxifen (TAM) with megestrol acetate (MA). Although it would be challenging to detect any covariate effect(s) of age with such little variability across most studies, conducting a sensitivity analysis removing individual trials for which covariate values are potentially a concern is possible.
Aggregate dichotomous patient-level covariatevisceral metastases
Cope et al. reported visceral metastases data (present, absent, or not reported) by presenting a network diagram together with pie-charts for each study next to the relevant comparison edge (see Cope et al. Fig. 5 ) [14] . We have visualized the visceral metastases covariate data via the 3D network plot system as the percentage of patients with the outcome. Where a proportion of patients were reported to have visceral metastases, the remaining proportion of patients had no visceral metastases. Furthermore, any trial not reporting the covariate of interest is clearly highlighted with a black circle on the 2D axis and labeled ''N/R.'' As displayed in Figures 6 and 7 , it is evident that there is variability in the proportion of patients with visceral metastases across the trials of the evidence network. The treatment comparisons that the trials with the most extreme values contribute to are also easily distinguishable (Figs. 6 and  7) . For example, the trials contributing to the comparisons of docetaxel with nab-paclitaxel, liposomal doxorubicin, or vinorelbine enrolled patients with the highest proportion of visceral metastases (87e91%). In comparison, all trials which included a treatment of TAM or MA included less than 50% of patients with visceral metastases.
Advanced application and features of the 3D network plot system

Reduction of data to a single covariate bar per treatment contrast
As an alternative to presenting covariate values for each trial, the system can be used to present an overall summary of the average covariate value across all trials for each treatment contrast. This allows for an overall summary of the level of the covariates for each treatment comparison. The exact influence a trial's covariate value has on estimation of NMA parameters varies by parameter and thus is difficult to represent by a single value [17] . Therefore, we suggest examining both the weighted and unweighted mean covariate value (weighting can be based on 1/variance of each trial's treatment effect). We have presented this summary for the covariate of disease duration in RA (example 3 data set). Here, the weighted mean of the covariate values (centered to the network weighted mean) is presented for all studies in a given treatment comparison (Fig. 8) . Fig. 8 can be compared with Fig. 2 to facilitate the comparison between presenting summary information per treatment contrast vs. all trial level evidence per contrast, respectively (although an unweighted mean was used to center the covariate values in Fig. 2 ). Note that there are three trials for the treatment contrast of placebo þ MTX compared with adalimumab þ MTX, two of which have a higher disease duration than the mean of the network, whereas a single trial has a lower disease duration than the mean of the network (Fig. 2) . However, for the treatment contrast of placebo þ MTX compared with adalimumab þ MTX, the summary of the covariate for this contrast is higher than the weighted mean of the network. 
Incorporation of data relating to the precision of outcome data
The width of the covariate bars is adjustable within the system. A good use for this functionality, to add more relevant information into the plot, as to further aid the interpretation of the data, is to make the bars proportional to the precision (1/variance) of the primary outcome for each of the trials. In this way, the precise trials, providing most information and thus being most influential in the synthesis, are more visually dominant (in the same way as having the central estimate of effect plotting symbol being proportional to the precision of the study in a conventional forest plot). Here, we have applied this approach to the RA example for the covariate of disease duration in a network which presents all trial-level covariate data ( Fig. 9 ) (example 4 data set) and a network which presents summary data for each contrast (Fig. 10 ) (example 5 data set). These plots illustrate the influence of each of the trials within the networks. For example, Abe 2006 is one of the smallest trials of the network, and it is clear from Fig. 9 that it has a small influence on the relative efficacy of infliximab þ MTX vs. placebo þ MTX compared with the two other trials contributing to this comparison (ATTEST and START trials). More generally, in Figures 9  and 10 , respectively, it is evident that the outcome data for the single trials contributing to the treatment contrasts of rituximab þ MTX and etanercept þ MTX vs. placebo þ MTX are associated with large variances (small precisions). Therefore, it is likely that the results from contrasts involving these treatment nodes will be associated with greater levels of uncertainty compared with other treatment nodes of the network.
Discussion
We have developed a novel interactive tool which produces a 3D version of a network diagram, incorporating the graphical representation of covariates on a third z-axis. The tool is available as an open access resource (available at http://3dnma.com/plot). We propose that this novel graphical approach can be used to facilitate the exploration of covariate distributions and imbalances across evidence networks. We believe it will be most valuable in the context of supporting NMA feasibility/validity assessments and aiding in the interpretation of NMA results.
In terms of NMA feasibility/validity assessments, the 3D network plot system can support this by aiding in the identification of (1) imbalances in covariates considered to be potential effect modifiers and (2) appropriate analyses to model and adjust for potential effect modifiers, identified as being imbalanced across treatment comparisons. Furthermore, the tool can aid in the interpretation of NMA results through (1) constructing the plots for using data from published NMAs as an appraisal/assessment tool to check that important covariate imbalances do not exist, in the presence of heterogeneity, for covariates not adjusted for in the original analysis and (2) reconciling the results of a meta-regression analysis through the impact of covariate adjustment vs. unadjusted model results via the visualization of covariate values across the whole network.
The proposed 3D plotting system was designed to provide a high level of flexibility and functionality to the user, be that data driven or visual. Most of the development was conducted within an AngularJS environment using a third party JavaScript library (Three.js) to create the 3D element of the application. By using Three.js, it was possible to rapidly develop the application as Three.js supported a large proportion of the processing required for 3D development. The 3D element of the plot was developed using data held within a specially formatted Microsoft Excel spreadsheet. The use of Microsoft Excel to develop the system means that the application is both intuitive and user friendly. The system is also able to accommodate the manual input of multi-arm trials although the examples presented in this publication include two-arm trials only (see example 6 data set from within the system).
In a pairwise meta-analysis context, exploratory plots of the data to explore potential associations between treatment effects and continuous study-level covariates are relatively straightforward. Such plots can also be overlaid with the results of a meta-regression analysis. Software is available to plot the effect size of individual studies against the covariate of interest [18] . This software incorporates a plotting symbol, where the size of the symbol is proportional to the precision of the study. A fitted regression line of best fit can then be superimposed on top of this together with associated confidence and/or Crlsdan example of which can be found in Ibrahim et al. 2015, Fig. 3 [19] . Work is underway to develop an approach to incorporate both study outcome/modeling results and study covariate values clearly for an NMA.
Future developments proposed for this application include the ability to produce stacked bar charts to visualize categorical covariates. In addition, integrating the system with an algorithm to optimally locate treatment nodes should help to make the network appear less cluttered [20] . One interesting option would be to further develop the 3D element of the system, such as allowing the system to be viewed in stereoscopic 3D (as found in virtual reality technologies) which may assist with interpretation [21] . The ability to print the networks using a 3D printer to produce real-life sculptures to further aid in the understanding and interpretation of evidence networks is now a possibility. As digital media replaces paper, some journals are now starting to permit publication of 3D figures and animations [22] . We would fully support this initiative in applied statistics and in medical research generally.
Conclusion
The 3D evidence network plot system is the first tool designed specifically to visualize covariate distributions and imbalances across evidence networks in 3D. This will be of primary interest to systematic review and metaanalysis researchers and, more generally, those assessing the validity and robustness of an NMA to inform reimbursement decisions. It will facilitate the exploration of covariate distributions and imbalances across evidence networks and be of most value in the context of supporting NMA feasibility/validity assessments and aid in the interpretation of NMA results. Given its free availability on the web and simple spreadsheet interface, it has the potential to make this powerful tool available to a wide audience.
